Genetic association, seasonal infections and autoimmune basis of narcolepsy

Journal of Autoimmunity

Volumn 43, Issue , 2013, Pages 26-31

  Singh, Abinav Kumar ^a   Mahlios, Josh ^a   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune; H1N1 infection; HLA association; Hypocretin; Narcolepsy

Indexed keywords

CATHEPSIN H; DNA METHYLTRANSFERASE 1; HLA DQB1 ANTIGEN; INFLUENZA VACCINE; OREXIN; OX40 LIGAND; PURINERGIC P2Y11 RECEPTOR;

2009 H1N1 INFLUENZA; ARTICLE; AUTOIMMUNE DISEASE; BRAIN REGION; BYSTANDER EFFECT; CATAPLEXY; CROSS REACTION; DAYTIME SOMNOLENCE; DISEASE COURSE; DNA METHYLATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HALLUCINATION; HUMAN; HYPOTHALAMUS; INFLUENZA A (H1N1); MOLECULAR MIMICRY; MUSCLE TONE; NARCOLEPSY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REM SLEEP DEPRIVATION; SEASONAL INFLUENZA; SEASONAL VARIATION; T LYMPHOCYTE;

AUTOANTIBODIES; AUTOIMMUNITY; GENETIC ASSOCIATION STUDIES; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; INFECTION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, IMMUNOLOGICAL; NARCOLEPSY; NEUROIMMUNOMODULATION; NEUROPEPTIDES; SEASONS;

EID: 84878361343     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.02.003     Document Type: Article

References (80)

1. Taheri S., Zeitzer J.M., Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annual Review of Neuroscience 2002, 25:283-313.
2. Okun M.L., Lin L., Pelin Z., Hong S., Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
3. Mohsenin V. Narcolepsy-master of disguise: evidence-based recommendations for management. Postgraduate Medicine 2009, 121:99-104.
4. Overeem S., Mignot E., van Dijk J.G., Lammers G.J. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society 2001, 18:78-105.
5. Anic-Labat S., Guilleminault C., Kraemer H.C., Meehan J., Arrigoni J., Mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999, 22:77-87.
6. Dauvilliers Y., Arnulf I., Mignot E. Narcolepsy with cataplexy. Lancet 2007, 369:499-511.
7. Aldrich M.S. The neurobiology of narcolepsy-cataplexy syndrome. International Journal of Neurology 1991, 25-26:29-40.
8. Nishino S., Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Medicine Reviews 2005, 9:269-310.
9. Mignot E.J. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 2012, 9:739-752.
10. Black J., Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006, 29:939-946.
11. Hogl B., Saletu M., Brandauer E., Glatzl S., Frauscher B., Seppi K., et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002, 25:905-909.
12. Mignot E., Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005, 28:754-763.
13. Nishino S., Okuro M. Emerging treatments for narcolepsy and its related disorders. Expert Opinion on Emerging Drugs 2010, 15:139-158.
14. Aldrich M.S. The neurobiology of narcolepsy-cataplexy. Progress in Neurobiology 1993, 41:533-541.
15. Aldrich M.S. Diagnostic aspects of narcolepsy. Neurology 1998, 50:S2-S7.
16. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Progress in Neurobiology 1997, 52:27-78.
17. Hagan J.J., Leslie R.A., Patel S., Evans M.L., Wattam T.A., Holmes S., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:10911-10916.
18. Sutcliffe J.G., de Lecea L. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. Journal of Neuroscience Research 2000, 62:161-168.
19. Brown R.E., Sergeeva O., Eriksson K.S., Haas H.L. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 2001, 40:457-459.
20. Shibata M., Mondal M.S., Date Y., Nakazato M., Suzuki H., Ueta Y. Distribution of orexins-containing fibers and contents of orexins in the rat olfactory bulb. Neuroscience Research 2008, 61:99-105.
21. Thorpy M. Therapeutic advances in narcolepsy. Sleep Medicine 2007, 8:427-440.
22. Jones B.E. Modulation of cortical activation and behavioral arousal by cholinergic and orexinergic systems. Annals of the New York Academy of Sciences 2008, 1129:26-34.
23. Foutz A.S., Mitler M.M., Cavalli-Sforza L.L., Dement W.C. Genetic factors in canine narcolepsy. Sleep 1979, 1:413-421.
24. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
25. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
26. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
27. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Medicine 2000, 6:991-997.
28. Thannickal T.C., Nienhuis R., Siegel J.M. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009, 32:993-998.
29. Horton R., Wilming L., Rand V., Lovering R.C., Bruford E.A., Khodiyar V.K., et al. Gene map of the extended human MHC. Nature Reviews Genetics 2004, 5:889-899.
30. Shiina T., Inoko H., Kulski J.K. An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 2004, 64:631-649.
31. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
32. Singal D.P., Blajchman M.A. Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes 1973, 22:429-432.
33. Dorman J.S., Bunker C.H. HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: a HuGE review. Epidemiologic Reviews 2000, 22:218-227.
34. van der Horst-Bruinsma I.E., Visser H., Hazes J.M., Breedveld F.C., Verduyn W., Schreuder G.M., et al. HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. Human Immunology 1999, 60:152-158.
35. Newton J.L., Harney S.M., Wordsworth B.P., Brown M.A. A review of the MHC genetics of rheumatoid arthritis. Genes and Immunity 2004, 5:151-157.
36. Simmonds M.J., Howson J.M., Heward J.M., Carr-Smith J., Franklyn J.A., Todd J.A., et al. A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect. Human Molecular Genetics 2007, 16:2149-2153.
37. Langdon N., Shindler J., Parkes J.D., Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 1986, 9:371-373.
38. Mignot E. Genetics of narcolepsy and other sleep disorders. American Journal of Human Genetics 1997, 60:1289-1302.
39. *0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994, 17:S60-S67.
40. *0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997, 48:1550-1556.
41. Mignot E., Lin L., Rogers W., Honda Y., Qiu X., Lin X., et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. American Journal of Human Genetics 2001, 68:686-699.
42. Hor H., Kutalik Z., Dauvilliers Y., Valsesia A., Lammers G.J., Donjacour C.E., et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nature Genetics 2010, 42:786-789.
43. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998, 50:S16-S22.
44. Hong S.C., Lin L., Jeong J.H., Shin Y.K., Han J.H., Lee J.H., et al. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Sleep 2006, 29:1429-1438.
45. Lin L., Hungs M., Mignot E. Narcolepsy and the HLA region. Journal of Neuroimmunology 2001, 117:9-20.
46. Tafti M., Maret S., Dauvilliers Y. Genes for normal sleep and sleep disorders. Annals of Medicine 2005, 37:580-589.
47. Dauvilliers Y., Maret S., Tafti M. Genetics of normal and pathological sleep in humans. Sleep Medicine Reviews 2005, 9:91-100.
48. Singh S.M., George C.F., Kryger M.H., Jung J.H. Genetic heterogeneity in narcolepsy. Lancet 1990, 335:726-727.
49. Hallmayer J., Faraco J., Lin L., Hesselson S., Winkelmann J., Kawashima M., et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nature Genetics 2009, 41:708-711.
50. Petrie H.T., Livak F., Burtrum D., Mazel S. T cell receptor gene recombination patterns and mechanisms: cell death, rescue, and T cell production. The Journal of Experimental Medicine 1995, 182:121-127.
51. Kornum B.R., Kawashima M., Faraco J., Lin L., Rico T.J., Hesselson S., et al. Common variants in P2RY11 are associated with narcolepsy. Nature Genetics 2011, 43:66-71.
52. Winkelmann J., Lin L., Schormair B., Kornum B.R., Faraco J., Plazzi G., et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Human Molecular Genetics 2012, 21:2205-2210.
53. Josefowicz S.Z., Wilson C.B., Rudensky A.Y. Cutting edge: TCR stimulation is sufficient for induction of Foxp3 expression in the absence of DNA methyltransferase 1. Journal of Immunology 2009, 182:6648-6652.
54. Faraco JLL, Kornum BR, Kenny EE, Trynka G, Einen M et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLOS Genetics, in press.
55. Rose N.R., Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunology Today 1993, 14:426-430.
56. Graus F., Saiz A., Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. Journal of Neurology 2010, 257:509-517.
57. Aran A., Lin L., Nevsimalova S., Plazzi G., Hong S.C., Weiner K., et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009, 32:979-983.
58. Tanaka S., Honda M. IgG abnormality in narcolepsy and idiopathic hypersomnia. PloS One 2010, 5:e9555.
59. Cvetkovic-Lopes V., Bayer L., Dorsaz S., Maret S., Pradervand S., Dauvilliers Y., et al. Elevated tribbles homolog 2-specific antibody levels in narcolepsy patients. The Journal of Clinical Investigation 2010, 120:713-719.
60. Kawashima M., Lin L., Tanaka S., Jennum P., Knudsen S., Nevsimalova S., et al. Anti-tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 2010, 33:869-874.
61. Sung H.Y., Francis S.E., Crossman D.C., Kiss-Toth E. Regulation of expression and signalling modulator function of mammalian tribbles is cell-type specific. Immunology Letters 2006, 104:171-177.
62. Eder K., Guan H., Sung H.Y., Ward J., Angyal A., Janas M., et al. Tribbles-2 is a novel regulator of inflammatory activation of monocytes. International Immunology 2008, 20:1543-1550.
63. Dalal J., Roh J.H., Maloney S.E., Akuffo A., Shah S., Yuan H., et al. Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation. Genes and Development 2013.
64. Dauvilliers Y., Montplaisir J., Cochen V., Desautels A., Einen M., Lin L., et al. Post-H1N1 narcolepsy-cataplexy. Sleep 2010, 33:1428-1430.
65. *0602-positive narcoleptic subjects with cataplexy. Biological Psychiatry 2005, 58:504-509.
66. Black J.L., Silber M.H., Krahn L.E., Fredrickson P.A., Pankratz V.S., Avula R., et al. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Sleep 2005, 28:427-431.
67. Tanaka S., Honda Y., Inoue Y., Honda M. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 2006, 29:633-638.
68. Smith A.J., Jackson M.W., Neufing P., McEvoy R.D., Gordon T.P. A functional autoantibody in narcolepsy. Lancet 2004, 364:2122-2124.
69. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PloS One 2012, 7:e33536.
70. Kwok R. Vaccines: the real issues in vaccine safety. Nature 2011, 473:436-438.
71. European Centre for Disease Prevention and Control (ECDC) VAESCO investigation into narcolepsy March 2012, http://wwwecdceuropaeu/en/activities/sciadvice/Lists/ECDC%2520Reviews/ECDC_DispFormaspx?List=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&ID=1017.
72. Han F., Lin L., Warby S.C., Faraco J., Li J., Dong S.X., et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Annals of Neurology 2011, 70:410-417.
73. Choe Y.J., Bae G.R., Lee D.H. No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: an ecological study. Vaccine 2012.
74. Matsuki K., Honda Y., Naohara T., Satake M., Someya T., Harada S., et al. Lymphocyte subsets in HLA-DR2-positive narcoleptic patients. Folia Psychiatrica et Neurologica Japonica 1985, 39:499-505.
75. Hinze-Selch D., Wetter T.C., Zhang Y., Lu H.C., Albert E.D., Mullington J., et al. In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology 1998, 50:1149-1152.
76. Morel S., Didierlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., et al. Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
77. Unutmaz D., Pileri P., Abrignani S. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. The Journal of Experimental Medicine 1994, 180:1159-1164.
78. Posner J.B., Dalmau J.O. Paraneoplastic syndromes affecting the central nervous system. Annual Review of Medicine 1997, 48:157-166.
79. Bataller L., Dalmau J.O. Paraneoplastic disorders of the central nervous system: update on diagnostic criteria and treatment. Seminars in Neurology 2004, 24:461-471.
80. Posner J.B., Dalmau J.O. Yet another paraneoplastic antibody. Annals of Neurology 2001, 49:141-142.